Effect of insulin pen devices on the management of diabetes mellitus

American Journal of Health-System Pharmacy

Volumn 65, Issue 11, 2008, Pages 1076-1082

  Meece, Jerry ^a  

^a Clinical Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN;

COST BENEFIT ANALYSIS; COST CONTROL; DEVICE; DIABETES MELLITUS; DRUG COST; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN PEN; INSULIN TREATMENT; NOTE; PATIENT SATISFACTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 44449138101     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070524     Document Type: Note

References (48)

1. Wild S, Roglic G, Green A et al. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27:1047-53.
2. Hogan P, Dall T, Nikolov P, for the American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care. 2003; 26:917-32.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837-53.
4. Koro CE, Bowlin SJ, Bourgeois N et al. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004; 27:17-20.
5. State of Diabetes in America report. www.aace.com/public/awareness/ stateofdiabetes/DiabetesAmericaReport.pdf (accessed 2007 Mar 1).
6. Gilmer TP, O'Connor PJ, Manning WG et al. The cost to health plans of poor glycemic control. Diabetes Care. 1997; 20:1847-53.
7. Shetty S, Secnik K, Oglesby AK. Relationship of glycemic control to total diabetes-related costs for managed care health plan members with type 2 diabetes. J Manag Care Pharm. 2005; 11:559-64.
8. Testa MA, Simonson DC. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus. A randomized, controlled, double-blind trial. JAMA. 1998; 280:1490-6.
9. Wagner EH, Sandhu N, Newton KM et al. Effect of improved glycemic control on health care costs and utilization. JAMA. 2001; 285:182-9.
10. Minshall ME, Roze S, Palmer AJ et al. Treating diabetes to accepted standards of care: a 10-year projection of the estimated economic and health impact in patients with type 1 and type 2 diabetes mellitus in the United States. Clin Ther. 2005; 27:940-50.
11. Hirsch IB, Bergenstal RM, Parkin CG et al. A real-world approach to insulin therapy in primary care practice. Clin Diabetes. 2005; 23:78-86.
12. Donnelly LA, Morris AD, Evans JM, for the DARTS/MEMO collaboration. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. QJM. 2007; 100:345-50.
13. Wright A, Burden AC, Paisey RB et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. (UKPDS 57). Diabetes Care. 2002; 25:330-6.
14. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006; 29:1963-72.
15. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes. 2002; 26(suppl 3):S18-24.
16. Ziemer DC, Miller CD, Rhee MK et al. Clinical inertia contributes to poor diabetes control in a primary care setting. Diabetes Educ. 2005; 31:564-71.
17. Coscelli C, Lostia S, Lunetta M et al. Safety, efficacy, acceptability of a pre-filled insulin pen in diabetic patients over 60 years old. Diabetes Res Clin Pract. 1995; 28:173-7.
18. Graff MR, McClanahan MA. Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. Clin Ther. 1998; 20:486-96.
19. Korytkowski M, Bell D, Jacobsen C et al. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003; 25:2836-48.
20. Lteif AN, Schwenk WF. Accuracy of pen injectors versus insulin syringes in children with type 1 diabetes. Diabetes Care. 1999; 22:137-40.
21. Puxty JA, Hunter DH, Burr WA. Accuracy of insulin injection in elderly patients. Br Med J. 1983; 287:1762.
22. Da Costa S. A co-ordinated approach to insulin transfer in the older type 2 patient. J Diabetes Nurs. 1997; 1:123-6.
23. Shelmet J, Schwartz S, Cappleman J et al. Preference and resource utilization in elderly patients: InnoLet versus vial/syringe. Diabetes Res Clin Pract. 2004; 63:27-35.
24. Kesson CM, Bailie GR. Do diabetic patients inject accurate doses of insulin? Diabetes Care. 1981; 4:333. Letter.
25. Gnanalingham MG, Newland P, Smith CP. Accuracy and reproducibility of low dose insulin administration using pen-injectors and syringes. Arch Dis Child. 1998; 79:59-62.
26. Keith K, Nicholson D, Rogers D. Accuracy and precision of low-dose insulin administration using syringes, pen injectors, and a pump. Clin Pediatr. 2004; 43:69-74.
27. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004; 27:1218-24.
28. Krapek K, King K, Warren SS et al. Medication adherence and associated hemoglobin A1c in type 2 diabetes. Ann Pharmacother. 2004; 38:1357-62.
29. Morris AD, Boyle DI, McMahon AD et al. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. Lancet. 1997; 350:1505-10.
30. Kuo YF, Raji MA, Markides KS et al. Inconsistent use of diabetes medications, diabetes complications, and mortality in older Mexican Americans over a 7-year period. Data from the Hispanic established population for the epidemiologic study of the elderly. Diabetes Care. 2003; 26:3054-60.
31. Albano S, for the ORBITER Study Group. Assessment of quality of treatment in insulin-treated patients with diabetes using a pre-filled insulin pen. Acta Biomed. 2004; 75:34-9.
32. Rubin RR, Peyrot M. Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premised 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies. Diabetes Care. 2004; 27:2495-7.
33. Summers KH, Szeinbach SL, Lenox SM. Preference for insulin delivery systems among current insulin users and nonusers. Clin Ther. 2004; 26:1498-505.
34. Lee WC, Balu S, Cobden D et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther. 2006; 28:1712-25.
35. Cobden D, Lee WC, Balu S et al. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy. 2007; 27:948-62.
36. Pawaskar MD, Camacho FT, Anderson RT et al. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther. 2007; 29:1294-305.
37. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care. 2003; 26:1902-12.
38. Davis S, Alonso MD. Hypoglycemia as a barrier to glycemic control. J Diabetes Complications. 2004; 18:60-8.
39. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329:977-86.
40. The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes. 1997; 46:271-86.
41. Currie CJ, Morgan CL, Poole CD et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin. 2006; 22:1523-34.
42. Balkrishnan R, Rajagopalan R, Camacho FT et al. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther. 2003; 25:2958-71.
43. Bullano MF, Al-Zakwani IS, Fisher MD et al. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products. Curr Med Res Opin. 2005; 21:291-8.
44. Heaton A, Martin S, Brelje T. The economic effect of hypoglycemia in a health plan. Manag Care Interface. 2003; 16:23-7.
45. Da Costa S, Brackenridge B, Hicks D. A comparison of insulin pen use in the United States and the United Kingdom. Diabetes Educ. 2002; 28:52-60.
46. Magnotti MA, Rayfield EJ. An update on insulin injection devices. Insulin. 2007; 2:173-81.
47. Riddle MC, Rosenstock J, Gerich J et al. The Treat-To-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003; 26:3080-6.
48. Meneghini L, Koenen C, Rojas PB et al. Efficacy and safety of insulin detemir in a large cohort of patients with type 2 diabetes using a simplified self-adjusted dosing guideline: results of the PREDICTIVE 303 study. Diabetes. 2007; 56:A51. Abstract.